To explore this possibility, we conducted a study presenting compelling evidence obtained with both mouse models and PXE patients that indeed ABCC6 deficiency promotes dyslipidemia and atherosclerosis in a haploinsufficient manner, with significant penetrance [54]. This evidence concerns the gene ABCC6 and metabolic syndrome.